Hledání v detailu akcií
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ0,00
KB0,00
PKN60,9560,98-0,67
Msft-1,00
Nokia3,75053,7995-0,41
IBM0,38
Mercedes-Benz Group AG57,5357,550,77
PFE-0,27
19.09.2024 2:04:00
Indexy online
AD Index online
select
AD Index online
 

  • 18.09.2024
Aldexa Therap (NASDAQ Cons)
Závěr k 18.9.2024 Změna (%) Změna (USD) Objem obchodů (ks)
5,87 1,56 0,09 317 728
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 19.09.2024
Popis společnosti
Obecné informace
Název společnostiAldeyra Therapeutics Inc
TickerALDX
Kmenové akcie:Ordinary Shares
RICALDX.O
ISIN-
Poslední známé roční výsledky31.12.2023
Poslední známé čtvrtletní výsledky30.06.2024
Počet zaměstnanců k 31.12.2023 10
Akcie v oběhu k 29.07.2024 59 421 551
MěnaUSD
Kontaktní informace
Ulice131 HARTWELL AVENUE, SUITE 320
MěstoLEXINGTON
PSČ02421
ZeměUnited States
Kontatní osobaDavid Burke
Funkce kontaktní osobyInvestor Relations
Telefon17 817 614 904
Fax13026365454
Kontatní telefon19 176 182 651

Business Summary: Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Aldeyra Therapeutics Inc revenues was not reported. Net loss increased 1% to $24.9M. Higher net loss reflects Research and development increase of 27% to $19.3M (expense), Interest income decrease of 3% to $3.4M (income). Basic Earnings per Share excluding Extraordinary Items remained flat at -$0.42.
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in Biotechnology (except Nanobiotechnology)
NAICSPharmaceutical Preparation Manufacturing
NAICS2007Research and Development in Biotechnology
NAICS2007Pharmaceutical Preparation Mfg
NAICS1997Research and Development in the Physical, Engineering, and Life Sciences
NAICS1997Pharmaceutical Preparation Manufacturing
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 19.09.2024
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
President, Chief Executive Officer, DirectorTodd Brady5223.01.201223.01.2012
Principal Financial Officer and Principal Accounting OfficerMichael Alfieri5831.08.202431.08.2024
Chief Development OfficerStephen Machatha4715.01.2019